查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790449

血液学和肿瘤学检测市场规模、份额和趋势分析报告：按产品、癌症、技术、最终用途、地区和细分市场预测，2025-2030 年

Hemato Oncology Testing Market Size, Share & Trends Analysis Report By Product (Assay Kits & Reagents, Services), By Cancer (Leukemia, Lymphoma), By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

血液学和肿瘤学检测市场概览

2024 年全球血液肿瘤检测市场规模估计为 36 亿美元，预计到 2030 年将达到 74.4 亿美元，2025 年至 2030 年的复合年增长率为 12.99%。血液肿瘤学涉及血液相关癌症和疾病的治疗、诊断和预防。

淋巴瘤和骨髓瘤盛行率的上升、个人化治疗需求的不断增长、血液系统恶性肿瘤诊断先进分子技术的普及以及药物和诊断联合开发的增多，是预测期内预计将推动血液肿瘤学发展的一些关键因素。分子诊断技术的快速发展改变了血液肿瘤学的格局，为各种血癌的检测、诊断、预后和治疗提供了精准且个人化的方法。这些最尖端科技显着提高了我们对疾病生物学和治疗反应的理解，从而改善了患者的预后并提高了临床工作流程的效率。

骨髓恶性肿瘤的分子诊断通常依赖即时PCR、萤光原位杂合反应(FISH) 和次世代定序(NGS) 等技术来检测特定的基因变异。例如，慢性骨髓性白血病(CML) 通常使用基于 PCR 的检测或针对 BCR:ABL1 融合基因的 FISH 检测进行诊断。 BCR/ABL 检测的国际标准化使得各实验室能够更轻鬆、更准确地诊断 CML。同样，急性骨髓性白血病(AML) 和急性淋巴细胞白血病 (ALL) 也受益于分子诊断，NGS 检测组能够同时识别多种基因突变，包括 FLT3-ITD、NPM1 和 TP53，这些突变对于风险分层和治疗选择至关重要。在淋巴瘤中，T细胞克隆性分析、标靶FISH和IgVH分析等技术已被广泛应用，而JAK2 V617F突变是高风险患者真性红血球增多症诊断的重要标誌。

最近的进展带来了更复杂的工具，包括单细胞定序、光学基因组图谱 (OGM) 和长读定序。单细胞定序在细胞层面提供了前所未有的分辨率，有助于深入了解克隆多样性和肿瘤演化。 《分子诊断学杂誌》最近发表的一项研究表明，OGM 能够有效识别结构突变和拷贝数变异，即使在低产量细胞群中也能对包括多发性骨髓瘤在内的肿瘤进行全面的细胞遗传学分析。这种泛基因组方法减少了对单一标记物特异性检测的需求，简化了工作流程并提高了诊断准确性。里尔大学医院的一项研究证实，OGM 可以减少完成基因组分析所需的细胞数量，与常规 FISH 检测的五种标记物的一致性达到 93%，并识别出超过 22 种额外的目标基因组突变。

2024年，牛津基因技术公司 (OGT) 推出了 SureSeq 髓系融合基因检测板 (SureSeq Myeloid Fusion Panel)，这是一款基于 RNA 的突破性 NGS 工具，旨在全面识别 AML 中的融合基因。该检测板由该公司与髓系癌领域的顶尖专家合作开发，涵盖 30 多个主要疾病相关融合基因，包括 KMT2A 和 MECOM，其配套的基因不可知方法能够在单次检测中检测稀有和新型融合基因。将此检测板整合到端对端 NGS 工作流程中，显着提高了样本分类能力，减少了对大量生物资讯资源的需求，并缩短了临床实验室的周转时间。

此外，Pacific Biosciences 和 Oxford Nanopore 等公司开发的长读长定序技术正在彻底改变这一领域，它们能够提供复杂基因组区域的完整且无误的读出结果。这些平台克服了短读长 NGS 的局限性，能够以无与伦比的精度检测结构变异、复杂的重排和拷贝数变异。

总的来说，这些先进的分子技术正在重塑血液肿瘤学的诊断格局，为临床医生提供个人化医疗的强大工具。该领域的持续创新有望进一步提高癌症诊断的准确性、速度和成本效益，最终改善患者的治疗效果并制定更个人化的治疗策略。

此外，淋巴瘤和骨髓瘤是美国最常见和临床上最重要的骨髓恶性肿瘤之一，对整体癌症负担有重大影响。

目录

第一章调查方法与范围

第二章执行摘要

第三章：血液学和肿瘤学检测市场的波动和范围

  • 市场体系展望
    • 母市场
    • 子公司市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 血液学和肿瘤学检测市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析
    • 法律规范

第四章血液学和肿瘤学检测市场：癌症类型、估计和趋势分析

  • 细分仪表板
  • 血液学和肿瘤学检测市场的癌症波动分析
  • 2018-2030 年血液学及肿瘤学检测市场规模及趋势分析（依癌症类型）
  • 白血病
    • 急性骨髓性白血病（AML）
  • 淋巴瘤
  • 骨髓增生性肿瘤
    • 真性红血球增多症（PV）
    • 原发性血小板增多症（ET）
    • 骨髓纤维化（MF）
  • 其他癌症

第五章血液学和肿瘤学检测市场：产品、估计和趋势分析

  • 细分仪表板
  • 血液学和肿瘤学检测市场产品差异分析
  • 2018-2030年血液学及肿瘤学检测市场规模及趋势分析（依产品）
    • 检测套件和试剂

第六章：血液学和肿瘤学检测市场：按技术进行的估计和趋势分析

  • 细分仪表板
  • 血液学和肿瘤学检测市场技术波动分析
  • 2018-2030年血液学及肿瘤学检测市场规模及趋势分析（依技术）
    • PCR
    • IHC
    • NGS
    • 细胞遗传学
    • 其他的

第七章血液学和肿瘤学检测市场：按最终用途的估计和趋势分析

  • 细分仪表板
  • 血液学和肿瘤学检测市场最终用途差异分析
  • 2018-2030年血液学及肿瘤学检测市场规模及趋势分析（依最终用途）
    • 医院
    • 学术研究机构
    • 其他的

第八章 竞争态势

  • 市场参与企业分类
  • 市场参与企业概况
  • 2024年市场分析（热图分析）
  • 战略地图
    • 合併与收购
    • 发射
    • 伙伴关係和合作
    • 扩张
    • 其他的
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • Abbott
    • EntroGen, Inc.
    • Qiagen NV
    • Cepheid（Danaher Corporation）
    • Thermo Fisher Scientific, Inc.
    • Bio-Rad Laboratories, Inc.
    • Illumina, Inc.
    • Amoy Diagnostics Co., Ltd.
    • ASURAGEN, INC
    • ArcherDX, Inc.（IDT）
  • 其他市场参与企业名单

第九章 重点

Product Code: GVR-4-68039-174-2

Hemato Oncology Testing Market Summary

The global hemato oncology testing market size was estimated at USD 3.60 billion in 2024 and is projected to reach USD 7.44 billion by 2030, growing at a CAGR of 12.99% from 2025 to 2030. Hemato oncology is associated with the treatment, diagnosis, and prevention of blood-related cancers and diseases.

Increasing prevalence of lymphoma & myeloma, growing demand for personalized therapy, availability of advanced molecular techniques for hemato-oncology diagnostics, and increasing drug-diagnostics co-development are some of the major factors anticipated to boost the growth of the market during the forecast period. The rapid evolution of molecular diagnostics has transformed the landscape of hemato-oncology, offering precise and personalized approaches for the detection, diagnosis, prognosis, and treatment of various blood cancers. These cutting-edge techniques have significantly improved the understanding of disease biology and therapeutic response, leading to better patient outcomes and more efficient clinical workflows.

Molecular diagnostics in hematologic malignancies often rely on methods like real-time PCR, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) to detect specific genetic alterations. For instance, chronic myeloid leukemia (CML) is routinely diagnosed using PCR-based tests targeting the BCR::ABL1 fusion gene or FISH assays. Standardization of BCR/ABL measurement internationally has facilitated easier and more accurate diagnosis of CML across laboratories. Similarly, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) benefit from molecular diagnostics, with NGS panels enabling the identification of multiple gene mutations simultaneously, including FLT3-ITD, NPM1, and TP53, which are critical for risk stratification and treatment selection. In lymphomas, techniques like T-cell clonality assays, targeted FISH, and IgVH analysis are widely employed, while the JAK2 V617F mutation serves as a critical marker for diagnosing polycythemia vera in high-risk patients.

Recent advancements have introduced more sophisticated tools such as single-cell sequencing, optical genome mapping (OGM), and long-read sequencing. Single-cell sequencing provides unprecedented resolution at the cellular level, offering insights into clonal diversity and tumor evolution. OGM, as demonstrated in a recent study published in The Journal of Molecular Diagnostics, enables comprehensive cytogenomic profiling of tumors, including multiple myeloma, by efficiently identifying structural variants and copy number changes even in low-yield cell populations. This pan-genomic approach reduces the need for separate, marker-specific tests, streamlining workflows and improving diagnostic accuracy. The study at Lille University Hospital confirmed that OGM can reduce the number of cells required for complete genomic profiling, showing 93% concordance with traditional FISH on five tested markers and identifying over 22 additional genomic variants of interest.

In 2024, Oxford Gene Technology (OGT) introduced the SureSeq Myeloid Fusion Panel, a groundbreaking RNA-based NGS tool designed for the comprehensive identification of fusion genes in AML. This panel, developed in collaboration with leading myeloid cancer experts, covers over 30 key disease-associated fusions, including KMT2A and MECOM, and employs a partner-gene agnostic approach to detect rare and novel fusions in a single assay. The integration of this panel into end-to-end NGS workflows has significantly enhanced the ability to classify samples, reducing the need for extensive bioinformatics resources and improving turnaround times in clinical laboratories.

Moreover, long-read sequencing technologies, such as those developed by Pacific Biosciences and Oxford Nanopore, are revolutionizing the field by providing complete, error-free readouts of complex genomic regions. These platforms are overcoming the limitations of short-read NGS, enabling the detection of structural variants, complex rearrangements, and copy number changes with unparalleled precision.

Collectively, these advanced molecular technologies are reshaping the diagnostic landscape in hemato-oncology, providing clinicians with powerful tools for personalized medicine. The continuous innovation in this space promises to further enhance the accuracy, speed, and cost-effectiveness of cancer diagnostics, ultimately leading to better patient outcomes and more personalized treatment strategies.

In addition, lymphoma and myeloma are among the most common and clinically significant hematologic malignancies in the United States, contributing significantly to the overall cancer burden.

Global Hemato Oncology Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the market trends in each of the sub-markets from 2018 to 2030. For this study, Grand View Research has segmented the global hemato oncology testing market report based on cancer, product, technology, end use, and region:

  • Cancer Outlook (Revenue, USD Million, 2018 - 2030)
  • Leukemia
    • Acute Myeloid Leukemia (AML)
    • Acute Lymphocytic Leukemia (ALL)
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
  • Lymphoma
    • Non-Hodgkin Lymphoma
    • Hodgkin Lymphoma
  • Myeloproliferative Neoplasms
    • Polycythemia vera (PV)
    • Essential thrombocythemia (ET)
    • Myelofibrosis (MF)
  • Other Cancers
  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Assay Kits and Reagents
  • Services
  • Technology Outlook (Revenue, USD Million, 2018 - 2030)
  • PCR
    • Real-time qPCR
    • Digital PCR
  • IHC
  • NGS
  • Cytogenetics
  • Others
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Academic and Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia
    • Singapore
    • South Korea
    • Thailand
  • Latin America
    • Argentina
    • Brazil
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hemato oncology testing Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of lymphoma & myeloma
      • 3.2.1.2. Growing demand for personalized therapy
      • 3.2.1.3. Availability of advanced molecular techniques for hemato oncology diagnostics
      • 3.2.1.4. Increasing drug-diagnostics co-development
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Favorable reimbursement scenario
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Hemato oncology testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal Landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental Landscape
    • 3.3.3. Regulatory Framework

Chapter 4. Hemato oncology testing Market: Cancer Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hemato oncology testing Market Cancer Movement Analysis
  • 4.3. Hemato oncology testing Market Size & Trend Analysis, By Cancer, 2018 - 2030 (USD Million)
  • 4.4. Leukemia
    • 4.4.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Acute Myeloid Leukemia (AML)
      • 4.4.2.1. Acute Myeloid Leukemia (AML) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.2. Acute Lymphocytic Leukemia (ALL)
        • 4.4.2.2.1. Acute Lymphocytic Leukemia (ALL) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.3. Chronic Lymphocytic Leukemia
        • 4.4.2.3.1. Chronic Lymphocytic Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.2.4. Chronic Myeloid Leukemia
        • 4.4.2.4.1. Chronic Myeloid Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Lymphoma
    • 4.5.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.1. Non-Hodgkin Lymphoma
        • 4.5.1.1.1. Non-Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.2. Hodgkin Lymphoma
        • 4.5.1.2.1. Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Myeloproliferative Neoplasms
    • 4.6.1. Myeloproliferative Neoplasms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2 Polycythemia vera (PV)
      • 4.6.2.1 Polycythemia vera (PV) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3 Essential thrombocythemia (ET)
      • 4.6.3.1 Essential thrombocythemia (ET) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4 Myelofibrosis (MF)
      • 4.6.4.1 Myelofibrosis (MF) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Other Cancers
    • 4.7.1. Other Cancers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hemato oncology testing Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Hemato oncology testing Market Product Movement Analysis
  • 5.3. Hemato oncology testing Market Size & Trend Analysis, By Product 2018 - 2030 (USD Million)
    • 5.3.1. Assay Kits and Reagents
      • 5.3.1.1. Assay Kits and Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.1.2. Services
        • 5.3.1.2.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hemato oncology testing Market: Technology Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Hemato oncology testing Market Technology Movement Analysis
  • 6.3. Hemato oncology testing Market Size & Trend Analysis, By Technology, 2018 - 2030 (USD Million)
    • 6.3.1. PCR
      • 6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.3.1.2. Real-time qPCR
        • 6.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.3.1.3. Digital PCR
        • 6.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. IHC
      • 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. NGS
      • 6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.4. Cytogenetics
      • 6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.5. Other Technologies
      • 6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Hemato oncology testing Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Hemato oncology testing Market End Use Movement Analysis
  • 7.3. Hemato oncology testing Market Size & Trend Analysis, By End Use 2018 - 2030 (USD Million)
    • 7.3.1. Hospitals
      • 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Academic & Research Institutes
      • 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Participants Overview
  • 8.3. Financial Performance
  • 8.4. Product Benchmarking
  • 8.5. Market Position Analysis, 2024 (Heat Map Analysis)
  • 8.6. Strategy Mapping
    • 8.6.1. Mergers and Acquisitions
    • 8.6.2. Launch
    • 8.6.3. Partnerships & Collaborations
    • 8.6.4. Expansion
    • 8.6.5. Others
  • 8.7. Company Profiles
    • 8.7.1. F. Hoffmann-La Roche Ltd
      • 8.7.1.1. Participant's overview
      • 8.7.1.2. Financial performance
      • 8.7.1.3. Product Benchmarking
      • 8.7.1.4. Strategic initiatives
    • 8.7.2. Abbott
      • 8.7.2.1. Participant's overview
      • 8.7.2.2. Financial performance
      • 8.7.2.3. Product Benchmarking
      • 8.7.2.4. Strategic initiatives
    • 8.7.3. EntroGen, Inc.
      • 8.7.3.1. Participant's overview
      • 8.7.3.2. Financial performance
      • 8.7.3.3. Product Benchmarking
      • 8.7.3.4. Strategic initiatives
    • 8.7.4. Qiagen N.V.
      • 8.7.4.1. Participant's overview
      • 8.7.4.2. Financial performance
      • 8.7.4.3. Product Benchmarking
      • 8.7.4.4. Strategic initiatives
    • 8.7.5. Cepheid (Danaher Corporation)
      • 8.7.5.1. Participant's overview
      • 8.7.5.2. Financial performance
      • 8.7.5.3. Product Benchmarking
      • 8.7.5.4. Strategic initiatives
    • 8.7.6. Thermo Fisher Scientific, Inc.
      • 8.7.6.1. Participant's overview
      • 8.7.6.2. Financial performance
      • 8.7.6.3. Product Benchmarking
      • 8.7.6.4. Strategic initiatives
    • 8.7.7. Bio-Rad Laboratories, Inc.
      • 8.7.7.1. Participant's overview
      • 8.7.7.2. Financial performance
      • 8.7.7.3. Product Benchmarking
      • 8.7.7.4. Strategic initiatives
    • 8.7.8. Illumina, Inc.
      • 8.7.8.1. Participant's overview
      • 8.7.8.2. Financial performance
      • 8.7.8.3. Product Benchmarking
      • 8.7.8.4. Strategic initiatives
    • 8.7.9. Amoy Diagnostics Co., Ltd.
      • 8.7.9.1. Participant's overview
      • 8.7.9.2. Financial performance
      • 8.7.9.3. Product Benchmarking
      • 8.7.9.4. Strategic initiatives
    • 8.7.10. ASURAGEN, INC
      • 8.7.10.1. Participant's overview
      • 8.7.10.2. Financial performance
      • 8.7.10.3. Product Benchmarking
      • 8.7.10.4. Strategic initiatives
    • 8.7.11. ArcherDX, Inc. (IDT)
      • 8.7.11.1. Participant's overview
      • 8.7.11.2. Financial performance
      • 8.7.11.3. Product Benchmarking
      • 8.7.11.4. Strategic initiatives
  • 8.8. List of Other Market Players

Chapter 9. Key Takeaways

List of Tables

  • Tables 1 List of Secondary Sources
  • Tables 2 List of Abbreviations
  • Tables 3 Hemato oncology testing market, by Cancer, 2018 - 2030 (USD Million)
  • Tables 4 Hemato oncology testing market, by Product, 2018 - 2030 (USD Million)
  • Tables 5 Hemato oncology testing market, by Technology, 2018 - 2030 (USD Million)
  • Tables 6 Hemato oncology testing market, by End Use, 2018 - 2030 (USD Million)
  • Tables 7 Company Overview
  • Tables 8 Service Benchmarking
  • Tables 9 Financial Performance
  • Tables 10 Strategic Initiatives

List of Figures

  • Fig. 1 Hemato oncology testing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 General methodology for a commodity flow analysis of Hemato oncology testing market
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Parent market analysis
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2024 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2024
  • Fig. 17 Hemato oncology testing market Dynamics
  • Fig. 18 Hemato oncology testing market: PORTER's analysis
  • Fig. 19 Hemato oncology testing market: PESTEL analysis
  • Fig. 20 Hemato oncology testing market by Cancer: Key Takeaways
  • Fig. 21 Hemato oncology testing market by Cancer, 2024 & 2030
  • Fig. 22 Leukemia market, 2018 - 2030 (USD Million)
  • Fig. 23 Acute Myeloid Leukemia (AML) market, 2018 - 2030 (USD Million)
  • Fig. 24 Acute Lymphocytic Leukemia (ALL) market, 2018 - 2030 (USD Million)
  • Fig. 25 Chronic Lymphocytic Leukemia market, 2018 - 2030 (USD Million)
  • Fig. 26 Chronic Myeloid Leukemia market, 2018 - 2030 (USD Million)
  • Fig. 27 Lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 28 Non-Hodgkin Lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 29 Hodgkin Lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 30 Myeloproliferative Neoplasms market, 2018 - 2030 (USD Million)
  • Fig. 31 Polycythemia vera (PV) market, 2018 - 2030 (USD Million)
  • Fig. 32 Essential thrombocythemia (ET) market, 2018 - 2030 (USD Million)
  • Fig. 33 Myelofibrosis (MF) market, 2018 - 2030 (USD Million)
  • Fig. 34 Other Cancers market, 2018 - 2030 (USD Million)
  • Fig. 35 Hemato oncology testing market by Product: Key Takeaways
  • Fig. 36 Hemato oncology testing market by Product, Market Share, 2024 & 2030
  • Fig. 37 Assay Kits and Reagents market, 2018 - 2030 (USD Million)
  • Fig. 38 Hemato oncology testing market by Technology: Key Takeaways
  • Fig. 39 Hemato oncology testing market by Technology, Market Share, 2024 & 2030
  • Fig. 40 PCR market, 2018 - 2030 (USD Million)
  • Fig. 41 Real-time qPCR market, 2018 - 2030 (USD Million)
  • Fig. 42 Digital PCR market, 2018 - 2030 (USD Million)
  • Fig. 43 IHC market, 2018 - 2030 (USD Million)
  • Fig. 44 NGS market, 2018 - 2030 (USD Million)
  • Fig. 45 Cytogenetics market, 2018 - 2030 (USD Million)
  • Fig. 46 Other technologies market, 2018 - 2030 (USD Million)
  • Fig. 47 Hemato oncology testing market by End Use Outlook: Key Takeaways
  • Fig. 48 Hemato oncology testing market by End Use Outlook, Market Share, 2024 & 2030
  • Fig. 49 Hospitals, 2018 - 2030 (USD Million)
  • Fig. 50 Academic & Research Institutes market, 2018 - 2030 (USD Million)
  • Fig. 51 Others market, 2018 - 2030 (USD Million)
  • Fig. 52 Market Participant Categorization
  • Fig. 53 Heat map analysis
  • Fig. 54 Strategic Framework